Big plans for MD Anderson's breast cancer program
Summer can be a quiet time at academic institutions, but things have been highly eventful for MD Anderson’s Breast Medical Oncology Department in the past couple of months.
Two significant recruitments were announced; including Debu Tripathy, M.D., an enthusiastic new chair with an optimistic view of his department’s role in improving care and expanding treatment options for patients facing the disease. And another addition made...
MD Anderson partners with Albert Einstein Hospital in Brazil
MD Anderson Cancer Center has announced a partnership with Hospital Israelita Albert Einstein (HIAE) to pioneer multidisciplinary patient...
Discovering a new way ovarian cancer spreads
Circulating tumor cells spread ovarian cancer through the bloodstream, homing in on a sheath of abdominal fatty tissue where it can grow and...
Treatment decisions traced back to diagnosing urologists
New research from MD Anderson Cancer Center is shedding light on the important role a diagnosing urologist plays in determining whether older men with low-risk prostate cancer receive treatment for their disease, and if so, what type of treatment they receive.
The study, published in JAMA Internal Medicine, examined why active surveillance, which involves monitoring the cancer closely with prostate-specific antigen (PSA) blood...
Largely overlooked, pseudogenes may help us understand biomarkers
Alas, the thankless pseudogene.
Dysfunctional, unloved and seemingly of little use, these poor-cousin relatives...
Examining side effects specific to each targeted drug
The main side effects of cytotoxic chemotherapy are notorious. But the side effects of newer, targeted molecular agents are less well known...
Welcome to Cancer Frontline
Dear colleagues,
I’m delighted to share with you Cancer Frontline from The University of Texas MD Anderson Cancer Center.
As...